Cerebrospinal fluid (CSF) plays a crucial role in Alzheimer's Disease (AD) and dementia research. In AD, abnormal accumulation of proteins like amyloid-beta and tau in the brain leads to cognitive decline. CSF acts as a conduit for these biomarkers, reflecting changes in their levels. Researchers use CSF analysis to detect early signs of AD by measuring amyloid-beta and tau proteins. Elevated levels of tau and decreased amyloid-beta in CSF are indicative of neurodegeneration and correlate with cognitive impairment. This fluid also helps in drug development, as changes in biomarkers can indicate treatment effectiveness. Understanding CSF dynamics enhances diagnostic accuracy and provides insights into disease progression, offering hope for earlier interventions and improved management strategies for AD and related dementias.
Jun Hua
Johns Hopkins University , United States
Nazneen N Dewji
Cenna Biosciences Inc, United States
Jacqueline London
Paris Diderot University, FranceSubmit your abstract Today
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neurophysiological change and cognitive response to levetiracetam in Alzheimer disease: Testing the missing mechanistic link
Christopher Hubler, Emergent Neural Systems Institute for Research, United States
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia